Nuclear Engineering and Technology

Korean Nuclear Society (한국원자력학회)
권호 표지
DOI QR코드

DOI QR Code

Prediction of radiation dose to adult human from radiopharmaceutical manufactured by third generation bisphosphonate labeled with Rhenium

  • Zahra Pourhabib (Department of Physics, Payame Noor University) ;
  • Hassan Ranjbar (Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute)
  • Received : 2021.08.14
  • Accepted : 2022.10.18
  • Published : 2023.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: The crucial step in preclinical process of radiopharmaceutical production is internal dosimetry evaluation by different ways to realize radiobiological dose-response relationships and to extract the results for clinical use. Till now several bone-seeking radiopharmaceuticals have been developed for bone metastasis. Interesting features of bisphosphonates attracted attentions to them in the field of radiopharmaceutical therapy and studies on new generation of them have been doing too. Materials and methods: In this study, we used ZNA as representative of the third generation. The radiopharmaceutical 188Re-ZNA was produced and its radiochemical purity was investigated. Then, the biological distribution of the produced radiopharmaceutical at 1, 2, 4 and 24 h after injection on different organs of mice were investigated. Finally, the absorbed dose of organs in the human body was assessed using the RADAR method. Results: The results show 96% radiochemical purity of the 188Re-ZNA radiopharmaceutical. The amount of %ID/g in bone is 1.131% after 1 h and in 24 h it has a significant amount compared to other organs, that is 0.516%. Also dosimetric results show that the highest absorption dose is related to bone and the amount of this dose is 0.050 mGy/MBq. Conclusion: Considering the possibility of producing the 188Re-ZNA radiopharmaceutical, as well as the proper distribution of this radiopharmaceutical in target and non-target organs and increasing the absorbed dose in bone, it can be concluded that this radiopharmaceutical can be useful in the "radiopharmaceutical therapy" in metastases.

Keywords

References

  1. J.A. Siegel, S.R. Thomas, J.B. Stubbs, et al., MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates, J. Nucl. Med. 40 (2) (1999) 37S-61S.
  2. A.L. Kesner, L. Bodei, Modern radiopharmaceutical dosimetry should include robust biodistribution reporting, Soc. Nucl. Med. (2018).
  3. B.J. McParland, Nuclear Medicine Radiation Dosimetry: Advanced Theoretical Principles, Springer Science & Business Media, 2010.
  4. Z. Pourhabib, H. Ranjbar, A. Bahrami Samani, Estimation of human dose of 188/186Re-HEDP cocktail based on OLINDA/EXM and distribution data in rats, Radiat. Protect. Dosim. 190 (2) (2020) 158-164. https://doi.org/10.1093/rpd/ncaa087
  5. H.M. Thierens, Radiopharmaceutical dosimetry, Encyclopedia of Medical Devices and Instrumentation (2006).
  6. M.R. Smith, Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond, in: Urologic Oncology: Seminars and Original Investigations, Elsevier, 2008.
  7. https://pubchem.ncbi.nlm.nih.gov/compound/Zoledronic-acid
  8. N. Kohno, K. Aogi, H. Minami, et al., Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial, J. Clin. Oncol. 23 (15) (2005) 3314-3321. https://doi.org/10.1200/JCO.2005.05.116
  9. H. Ranjbar, A. Bahrami-Samani, M.R. Yazdani, et al., Determination of human absorbed dose of cocktail of 153 Sm/177 Lu-EDTMP, based on biodistribution data in rats, J. Radioanal. Nucl. Chem. 307 (2) (2016) 1439-1444. https://doi.org/10.1007/s10967-015-4324-x
  10. M.G. Stabin, J.A. Siegel, Physical models and dose factors for use in internal dose assessment, Health Phys. 85 (3) (2003) 294-310. https://doi.org/10.1097/00004032-200309000-00006
  11. M.G. Stabin, R.B. Sparks, E. Crowe, OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine, J. Nucl. Med. 46 (6) (2005) 1023-1027.
  12. G.B. Saha, Fundamentals of Nuclear Pharmacy, fifth ed., Springer, New York, 2004.
  13. A. Lahooti, S. Shanehsazzadeh, A.R. Jalilian, et al., Assessment of effective absorbed dose of 111In-DTPA-Buserelin in human on the basis of bio-distribution rat data, Radiat. Protect. Dosim. 154 (1) (2013) 1-8. https://doi.org/10.1093/rpd/ncs137